Bull and Bear
Bull and Bear
Verdict: Lean Long, Wait For Confirmation — CNC's Q1 FY2026 earnings beat and 16% FCF yield create a compelling risk/reward if Medicaid margin recovery sustains through Q2-Q3, but the OBBBA's structural impact on Medicaid membership and Marketplace contraction from expired APTCs introduce genuine uncertainty about normalized earnings power. The tension that matters most is whether Medicaid HBR improvement is cyclical recovery (bull wins) or a brief respite before OBBBA-driven morbidity deterioration overwhelms rate increases (bear wins). Two more quarters of Medicaid HBR below 93.5% would shift this verdict to Lean Long with conviction.
Bull Case
Bull's price target: $90, derived from 15x P/E on $6.00 normalized EPS (FY2027E). Timeline: 18-24 months. Primary catalyst: sustained Medicaid HBR improvement through Q2-Q3 FY2026. Disconfirming signal: Medicaid HBR reverses above 94% for two consecutive quarters.
Bear Case
Bear's downside target: $30, derived from 10x P/E on $3.00 adjusted EPS in a scenario where membership declines accelerate and margins fail to normalize. Timeline: 12-18 months. Primary trigger: Medicaid HBR reverses above 94% with accelerating membership loss. Cover signal: two consecutive quarters of Medicaid HBR below 92%.
The Real Debate
Verdict
Verdict: Lean Long, Wait For Confirmation. The bull case carries more weight because Q1 FY2026 delivered concrete evidence of margin recovery — not guidance, not promises, but a $0.50 earnings beat with improving Medicaid HBR. The 16% FCF yield provides a substantial margin of safety even if normalized earnings land at $4-5 rather than $6-7. The most important tension is whether the Medicaid HBR improvement is durable through the OBBBA implementation period. The bear is right that structural Medicaid membership erosion and Marketplace contraction are real — these are not cyclical headwinds but permanent policy shifts. However, the bear's case requires that rate inadequacy persists, and the evidence from Q1 FY2026 (composite rate yield of 4.5%, HBR improving for three consecutive quarters) suggests rates are in fact catching up. The condition that would change this verdict to Avoid: Medicaid HBR reversal above 94% combined with loss of Georgia or Texas Medicaid contracts, which would signal both margin and membership deterioration simultaneously.
Verdict: Lean Long, Wait For Confirmation — Q1 FY2026 margin recovery is real but needs Q2-Q3 confirmation before full conviction. At 16% FCF yield, the price compensates for risk if margins merely stabilize, let alone recover.